Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 138 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…
Lyra Therapeutics Announces First Patient Enrolled In Pivotal ENLIGHTEN II Clinical Trial Of LYR-210 In Chronic Rhinosinusitis Patients
Lyra Therapeutics, Inc. (NASDAQ:LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to
Lyra Therapeutics’s Return On Capital Employed Overview
Benzinga Pro data, Lyra Therapeutics (NASDAQ:LYRA) reported Q2 sales of $407 thousand. Earnings fell to a loss of $14.48 million, resulting in a 106.56% decrease from last quarter.
Lyra Therapeutics Q2 EPS $(0.43) Up From $(0.85) YoY
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.43) per share. This is a 49.41 percent increase over losses of $(0.85) per share from the same period last year.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million.
Lyra Therapeutics’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Lyra Therapeutics's (NASDAQ:LYRA) reported sales totaled $5.37 million. Despite a 48.51% increase in earnings, the company posted a loss of $7.01 million.